Tag Archives: Oncology

Workforce Shortage in Oncology Imminent

By Jennifer Ringler | Published: December 13, 2010
Supply and demand for oncology specialists is expected to become even more unbalanced in the US market over the next 10 years, particularly as the new health reform legislation creates more uncertainty for the reimbursement of the high cost biologic treatments now coming on stream. Several survey are documenting the shortage and suggesting that the [...]
Posted in Agency Insight, News | Tagged | 2 Comments

Cancer Testing Times: One Thing the UK Will Not Be Cutting

By Julian Upton | Published: October 27, 2010
Buried among the savage, £83 billion-worth of cuts announced by the UK coalition government’s controversial Comprehensive Spending Review last week was confirmation that the Department of Health would not be taking forward the previous government’s pledge to introduce a one-week target for cancer testing. Under the Labour government, the time that it took for a patient [...]
Posted in Europe, Global, Guest Blog | Also tagged , , , | Leave a comment

Financial Woes Affect Cancer Patients’ Treatment Decisions

By Jennifer Ringler | Published: October 8, 2010
A recent survey conducted by MDLinx reveals that 95 percent of the nation’s oncologists report a rise in their patients’ concerns over treatment costs in the past six months. Of the 106 US oncologists surveyed in a MDLinx survey last month, 84 percent said they had invested more time and effort into the financial planning of [...]
Posted in News | Also tagged | Leave a comment

Options for Oncologists Get Tougher

By William Looney | Published: August 4, 2010
How does the business of oncology practice fare today? The National Comprehensive Cancer Care Network (NCCN), which allies 21 of the world’s leading cancer care and research centers in developing state-of-the-art practice guidelines, decided to ask that question in a survey it conducted among several hundred oncology specialists earlier this year. The results, a sobering [...]
Posted in Strategy | Also tagged , | 2 Comments

Abbott Shells Out $3.7 Billion for Piramal

By Oriana Schwindt | Published: May 26, 2010
In July 2009, judging solely by total revenue, Abbott was assigned the rank of the eighth-largest pharmaceutical company in the Fortune Global 500. Nearly a year later, the company is looking to move up at least a few notches. On May 21, Abbott acquired Indian generic giant Piramal for a cool $2.12 billion up front, [...]
Posted in Strategy | Also tagged , , , , , , , , | Leave a comment